SBRT for Ventricular Arrhythmia
ConditionVentricular Arrythmia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedical University of Graz
About this trial
The aim of this study is to demonstrate the safety and efficacy of STAR (Stereotactic Antiarrhythmic Radiotherapy) in patients with VT (ventricular tachycardia) who are unresponsive to standard treatments. Additionally, the planned study aims to provide further insights into the effects of STAR on VT burden, ICD interventions, and insights regarding late toxicities, particularly those related to the heart, which are currently not well understood.
Eligibility criteria
Qualifiers
Recurrent VTs/VES with significant burden despite guideline-directed therapy
Existing protective ICD (Implantable cardioverter-defibrillator) implantation except in the presence of contraindications
AND lack of response or intolerance to antiarrhythmic medication
AND status post ≥1 catheter ablation due to monomorphic VT(s) and VT early recurrence (<12 months after the last catheter ablation) OR contraindication for endocardial ablation (mechanical valve prosthesis, LV (left ventricular) thrombus, or lack of vascular access in suspicion of endocardial substrate)
Disqualifiers
Acute myocardial infarction or percutaneous coronary intervention or heart surgery (<3 months before study enrollment)
Status post intra-thoracic pre-radiation
Immediate proximity to radiosensitive structures (e.g., esophagus) making therapy unsafe to administer
Advanced symptomatic heart failure (NYHA Class IV)
Trial design
Treatments tested in this trial
- Stereotactic Antiarrhythmic Radiotherapy
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov